Clinical Trials News

Latest Clinical Trials / Drug Trials News From Medical News Today.

Total news: 25
Last news: August 31, 2007 08:00:00

Dia-B Tech Limited (ASX:DIA) has achieved a major clinical milestone of its ISF402 diabetes drug development by confirming its detection in the bloodstream of trial patients. Peptides and proteins already existing in the bloodstream often mask small peptide drugs, making drug evaluation unreliable. A robust procedure has been developed for measuring ISF402 in plasma. [click link for full article] - [Read more]

Merck Serono, a division of Merck KGaA, announced that a phase II trial investigating the humanized monoclonal antibody matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity. Merck Serono is therefore reconsidering further development of matuzumab in mCRC at this stage. [click link for full article] - [Read more]

Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin agonist drug candidate, for the treatment of male erectile dysfunction (ED). The decision follows responses from representatives of the U.S. [click link for full article] - [Read more]

Cardium Therapeutics (AMEX:CXM) announced that positive findings from pooled by-patient analysis of the AGENT-3 and AGENT-4 Phase 2b/3 clinical trials will be published in the September 11, 2007 issue of the Journal of the American College of Cardiology (JACC) and is now available online. [click link for full article] - [Read more]

ICON plc (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries announced that it has initiated its 100th trial using electronic data capture Electronic Data Capture (EDC). EDC technology is designed for the collection of clinical data in electronic format for use in clinical trials. [click link for full article] - [Read more]

Immutep S.A., a biopharmaceutical company specialised in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced that its lead product, ImmuFact(R) IMP321, has entered a Phase I clinical trial in metastatic melanoma in a novel protocol combining adoptive T cell transfer after transient lymphodepletion associated with peptide vaccination. [click link for full article] - [Read more]

Lorus Therapeutics Inc. [click link for full article] - [Read more]

Prolexys Pharmaceuticals, Inc. announced that its first-in-humans Phase 1 study of PRLX 93936 has begun. This open-label trial is designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of PRLX 93936 in patients with advanced solid tumors. Study sites include TGen Clinical Research at Scottsdale Healthcare in Scottsdale, Arizona, and Tower Cancer Research Foundation in Beverly Hills, California. [click link for full article] - [Read more]

University of Minnesota researchers have discovered that treating people who have early cardiovascular abnormalities, but show no symptoms of cardiovascular disease, can slow progression and even reverse damage to the heart and blood vessels.In a recent double-blind study, researchers enrolled 76 asymptomatic subjects with early markers for cardiovascular disease, based on a 10-factor scale called the Rasmussen Disease Score. [click link for full article] - [Read more]

CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, in combination with the anthracycline idarubicin for the treatment of Acute Myeloid Leukemia (AML). The trial is being conducted at multiple sites in the European Union. [click link for full article] - [Read more]

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed enrollment and initial dosing ahead of schedule in ACHIEVE 1, the first of two pivotal Phase 3 trials of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006. [click link for full article] - [Read more]

Baxter International Inc. (NYSE: BAX) and The Alzheimers Disease Cooperative Study (ADCS) group today announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV), an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate alzheimers disease. [click link for full article] - [Read more]

If you scratch an area of your skin, levels of two blood chemicals rise accordingly, say scientists from the Chinese University of Hong Kong. This new discovery, they say, could lead the way to devising new treatments for eczema and itching. You can read about this in the British Journal of Dermatology.The researchers had 28 children wear a device they called a DigiTrac monitor on their dominant wrist while sleeping. [click link for full article] - [Read more]

Dr. Sam Raz knew that he was onto something when he heard that all of the women who had taken part in clinical trials of a new device developed by Israeli start-up Flexiprobe to treat incontinence, asked if they could take the device home with them afterwards. "It was very popular with the patients who tried it, and that gave us great encouragement. Its what convinced me to get involved with the project," says Raz, who joined the company as its CEO a year ago. [click link for full article] - [Read more]

Sanofi-aventis U.S. launched a new 200 mg single-use vial of its chemotherapy treatment Eloxatin(R) (oxaliplatin injection) for patients who have adjuvant stage III colon cancer and advanced colorectal cancer, which is expected to offer more convenience, efficiency and safety in the preparation of the injectable cancer drug. Previously, Eloxatin(R) had been available in 50 mg and 100 mg single- use vials. [click link for full article] - [Read more]

CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the completion of enrollment of its pivotal clinical study for the treatment of atrial fibrillation. Ed Brennan, Ph.D. Chief Executive Officer of CryoCor, said, "This is a major milestone for CryoCor, being the first company to complete enrollment in a randomized pivotal study for the use of ablation for the treatment of atrial fibrillation. [click link for full article] - [Read more]

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]). [click link for full article] - [Read more]

Novo Nordisk announced clinical results from the second and third of five phase 3 studies with liraglutidev the once daily human GLP 1 analogue. The two 26 week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes) programme and comprised 2,132 patients in total. The two studies investigated the effect of different doses of liraglutide in combination with a single oral antidiabetic drug. [click link for full article] - [Read more]

New data suggest that patients with fibromyalgia treated with 60mg or 120mg of Cymbalta® (duloxetine HCl) experienced greater reduction in pain severity beginning one week after starting duloxetine than those taking placebo (sugar pill), as measured by the Brief Pain Inventory Average Pain Score (BPI). [click link for full article] - [Read more]

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today the publication of results demonstrating that patients treated with TYSABRI® (natalizumab) showed a significant improvement in health-related quality of life (HRQoL) measures when compared to placebo. These results are from the first Phase III multiple sclerosis (MS) studies that have demonstrated improvement on HRQoL measures in patients with relapsing forms of MS. [click link for full article] - [Read more]